New: NCI-funded clinical trial search
Mednet Logo

How do you approach the choice between 3-fx and 5-fx postop SRS for a resected brain metastasis for intermediate cavity volume?

A071801 used 27 Gy/3 for cavities <30 cc and 30 Gy/5 for >30 cc. Is there a biological rationale for that size cutoff/dosing? This question is part of our ASTRO 2026 collaboration, inspired by the Plenary Session Presentation "Alliance A071801 Phase III Trial Postoperative Single Fraction Stereotactic Radiosurgery (SRS) vs. Fractionated SRS (fSRS) for Resected Brain Metastasis" by Dr. Paul Brown, MD
2 Answers
Mednet Member
Radiation Oncology · Carolinas Medical Center
Answered on

In my practice, I generally use single-fraction SRS for lesions/cavities smaller than 2 cm in maximum dimension or ~4 cc in volume to 18 - 20 Gy, but this is a relatively rare occurrence given the fact that resected brain metastases tend to be larger.

For cavities larger than 2 cm (or about 4 cc volume), I use 27 Gy in 3 fractions as my standard dose regimen for cavities up to 4 cm maximum dimension or about 30 to 33 cc volume. The best data for this approach comes from the Stanford Phase I/2 trial (Klebaner et al., PMID 40089071), where the late radiation necrosis rate for cavities up to 4 cm / 33.5 cc was 33% (2 of 6 patients) at the dose of 30 Gy in 3 fractions vs. 0% at the 27 Gy in 3 fractions dose level.

30 Gy in 5 fractions is an isoef...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert
Radiation Oncology · Harvard Medical School
Answered on

Yes, decreasing the dose per fraction is a great way to increase normal tissue safety, with a small tradeoff of increasing a few more fractions. Increasing from 1 fraction to multiple fractions has enabled effective yet safe short-course radiation treatments. How few fractions we can do safely is dependent on several factors; foremost are volume of normal tissue exposure and location in the brain or other normal tissues collaterally irradiated. Other factors to consider are systemic therapies that may increase risk of inflammation or injury acutely or delayed, age, co-morbidities with increased radiation sensitivity, and disease prognosis. Following the practice of A071801 is a great start, but if there are ever concerns for safety, decreas...

Join for free or sign in to see the full answer